Nephro-Urology Monthly

Published by: Kowsar

Triggers, Bullets and Targets, Puzzle of Membranous Nephropathy

Mohammadreza Ardalan 1 , 2 , *
Author Information
1 Nephrology Department, Tabriz University of Medical sciences, Tabriz, IR Iran
2 Mario NegriInstitute of Pharmacological Research, Bergamo, Italy
Article information
  • Nephro-Urology Monthly: September 01, 2012, 4 (4); 599-602
  • Published Online: September 24, 2012
  • Article Type: Review Article
  • Received: September 16, 2011
  • Revised: October 13, 2011
  • Accepted: October 25, 2011
  • DOI: 10.5812/numonthly.2330

To Cite: Ardalan M. Triggers, Bullets and Targets, Puzzle of Membranous Nephropathy, Nephro-Urol Mon. 2012 ; 4(4):599-602. doi: 10.5812/numonthly.2330.

Abstract
Copyright © 2012, Nephrology and Urology Research Center. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Introduction
2. Materials and Methods
3. Results and Discussion
4. Conclusions
Acknowledgements
Footnotes
References
  • 1. Beck LH, Jr, Bonegio RG, Lambeau G, Beck DM, Powell DW, Cummins TD, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. 2009; 361(1): 11-21[PubMed]
  • 2. Hoxha E, Harendza S, Zahner G, Panzer U, Steinmetz O, Fechner K, et al. An immunofluorescence test for phospholipase-Areceptor antibodies and its clinical usefulness in patients with membranous glomerulonephritis. Nephrol Dial Transplant. 2011; 26(8): 2526-32[DOI][PubMed]
  • 3. Murtas C, Ravani P, Ghiggeri GM. New insights into membranous glomerulonephritis: from bench to bedside. Nephrol Dial Transplant. 2011; 26(8): 2428-30[DOI][PubMed]
  • 4. Debiec H, Ronco P. Nephrotic syndrome: A new specific test for idiopathic membranous nephropathy. Nat Rev Nephrol. 2011; 7(9): 496-8[PubMed]
  • 5. Qin W, Beck LH, Jr, Zeng C, Chen Z, Li S, Zuo K, et al. Anti-phospholipase A2 receptor antibody in membranous nephropathy. J Am Soc Nephrol. 2011; 22(6): 1137-43[DOI][PubMed]
  • 6. Hofstra JM, Beck LH, Jr, Beck DM, Wetzels JF, Salant DJ. Anti-phospholipase A receptor antibodies correlate with clinical status in idiopathic membranous nephropathy. Clin J Am Soc Nephrol. 2011; 6(6): 1286-91[DOI][PubMed]
  • 7. Debiec H, Martin L, Jouanneau C, Dautin G, Mesnard L, Rondeau E, et al. Autoantibodies specific for the phospholipase A2 receptor in recurrent and De Novo membranous nephropathy. Am J Transplant. 2011; 11(10): 2144-52[DOI][PubMed]
  • 8. Schaloske RH, Dennis EA. The phospholipase A2 superfamily and its group numbering system. Biochim Biophys Acta. 2006; 1761(11): 1246-59[DOI][PubMed]
  • 9. Nevalainen TJ, Kanchanapangka S, Youngprapakorn P, Webb GJW, Manolis SC, Scott KF. Phospholipase A2 activity of crocodile serum. Amphibia-Reptilia. 2009; 30: 119-25[PubMed]
  • 10. Saari KM, Aho V, Paavilainen V, Nevalainen TJ. Group II PLA(2) content of tears in normal subjects. Invest Ophthalmol Vis Sci. 2001; 42(2): 318-20[PubMed]
  • 11. Fry BG, Vidal N, Norman JA, Vonk FJ, Scheib H, Ramjan SF, et al. Early evolution of the venom system in lizards and snakes. Nature. 2006; 439(7076): 584-8[DOI][PubMed]
  • 12. Lin MK, Farewell V, Vadas P, Bookman AA, Keystone EC, Pruzanski W. Secretory phospholipase A2 as an index of disease activity in rheumatoid arthritis. Prospective double blind study of 212 patients. J Rheumatol. 1996; 23(7): 1162-6[PubMed]
  • 13. Granata F, Petraroli A, Boilard E, Bezzine S, Bollinger J, Del Vecchio L, et al. Activation of cytokine production by secreted phospholipase A2 in human lung macrophages expressing the Mtype receptor. J Immunol. 2005; 174(1): 464-74[PubMed]
  • 14. Cybulsky AV, Quigg RJ, Salant DJ. Experimental membranous nephropathy redux. Am J Physiol Renal Physiol. 2005; 289(4)-71[DOI][PubMed]
  • 15. Debiec H, Guigonis V, Mougenot B, Decobert F, Haymann JP, Bensman A, et al. Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase antibodies. N Engl J Med. 2002; 346(26): 2053-60[DOI][PubMed]
  • 16. Debiec H, Nauta J, Coulet F, van der Burg M, Guigonis V, Schurmans T. Role of truncating mutations in MME gene in fetomaternal alloimmunisation and antenatal glomerulopathies. Lancet. 2004; 364(9441): 1252-9[DOI]
  • 17. Makker SP, Tramontano A. Idiopathic membranous nephropathy: an autoimmune disease. Semin Nephrol. 2011; 31(4): 333-40[DOI][PubMed]
  • 18. Debiec H, Lefeu F, Kemper MJ, Niaudet P, Deschenes G, Remuzzi G, et al. Early-childhood membranous nephropathy due to cationic bovine serum albumin. N Engl J Med. 2011; 364(22): 2101-10[DOI][PubMed]
  • 19. Polanco N, Gutierrez E, Covarsi A, Ariza F, Carreno A, Vigil A, et al. Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy. J Am Soc Nephrol. 2010; 21(4): 697-704[DOI][PubMed]
  • 20. Cravedi P, Ruggenenti P, Remuzzi G. Circulating anti-PLA2R autoantibodies to monitor immunological activity in membranous nephropathy. J Am Soc Nephrol. 2011; 22(8): 1400-2[DOI][PubMed]
  • 21. Fervenza FC, Abraham RS, Erickson SB, Irazabal MV, Eirin A, Specks U, et al. Rituximab therapy in idiopathic membranous nephropathy: a 2-year study. Clin J Am Soc Nephrol. 2010; 5(12): 2188-98[DOI][PubMed]
  • 22. Remuzzi G, Chiurchiu C, Abbate M, Brusegan V, Bontempelli M, Ruggenenti P. Rituximab for idiopathic membranous nephropathy. Lancet. 2002; 360(9337): 923-4[DOI]
  • 23. Cravedi P, Sghirlanzoni MC, Marasa M, Salerno A, Remuzzi G, Ruggenenti P. Efficacy and safety of rituximab second-line therapy for membranous nephropathy: a prospective, matched-cohort study. Am J Nephrol. 2011; 33(5): 461-8[DOI][PubMed]
  • 24. Fornoni A, Sageshima J, Wei C, Merscher-Gomez S, Aguillon-Prada R, Jauregui AN, et al. Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Sci Transl Med. 2011; 3(85): 85ra46[DOI][PubMed]
  • 25. Ruggenenti P, Cravedi P, Sghirlanzoni MC, Gagliardini E, Conti S, Gaspari F, et al. Effects of rituximab on morphofunctional abnormalities of membranous glomerulopathy. Clin J Am Soc Nephrol. 2008; 3(6): 1652-9[DOI][PubMed]
  • 26. Sprangers B, Lefkowitz GI, Cohen SD, Stokes MB, Valeri A, Appel GB, et al. Beneficial effect of rituximab in the treatment of recurrent idiopathic membranous nephropathy after kidney transplantation. Clin J Am Soc Nephrol. 2010; 5(5): 790-7[DOI][PubMed]
  • 27. Bomback AS, Derebail VK, McGregor JG, Kshirsagar AV, Falk RJ, Nachman PH. Rituximab therapy for membranous nephropathy: a systematic review. Clin J Am Soc Nephrol. 2009; 4(4): 734-44[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .
Readers' Comments